ISRCTN ISRCTN17799325
DOI https://doi.org/10.1186/ISRCTN17799325
Integrated Research Application System (IRAS) 1013081
CRO Code Quotient Sciences Code: QSC302976
Sponsor Epygenix Therapeutics, Inc.
Funder Epygenix Therapeutics, Inc.
Submission date
29/06/2026
Registration date
03/07/2026
Last edited
05/08/2026
Recruitment status
No longer recruiting
Overall study status
Deferred
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Dr David Everton
Principal investigator

Mere Way, Ruddington Fields
Ruddington
Nottingham
NG11 6JS
United Kingdom

Phone +44 (0)3303031000
Email recruitment@weneedyou.co.uk
Dr Robert Faulkner
Public, Scientific

Harmony Biosciences
630 W. Germantown Pike, Suite 215
Plymouth Meeting
PA 19462
United States of America

Phone +1 817-773-1958
Email rfaulkner@harmonybiosciences.com

Study information

Primary study designInterventional
AllocationN/A: single arm study
MaskingOpen (masking not used)
ControlUncontrolled
AssignmentSingle
PurposePhase I trial in healthy volunteers
Scientific titleDeferred registration: Quotient Sciences code: QSC302976 [Full scientific title to be added on or before the deferral expiry date]
Study objectives This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Ethics approval(s)

Approved 31/07/2026, South Central - Berkshire Research Ethics Committee (Health Research Authority, 2 Reman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8178; berkshire.rec@hra.nhs.uk), ref: 26/SC/0071

Health condition(s) or problem(s) studiedHealthy volunteers
InterventionThis is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Intervention typeDrug
PhasePhase I
Drug / device / biological / vaccine name(s)This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Primary outcome measure(s)
  1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Key secondary outcome measure(s)
Completion date17/09/2026

Eligibility

Participant type(s)
Age groupMixed
Lower age limit30 Years
Upper age limit65 Years
SexMale
Target sample size at registration8
Key inclusion criteriaThis is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Key exclusion criteriaThis is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.
Date of first enrolment11/08/2026
Date of final enrolment17/09/2026

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Quotient Sciences Limited
Mere Way, Ruddington Fields
Ruddington
Nottingham
NG11 6JS
England

Results and Publications

Individual participant data (IPD) Intention to shareNo

Editorial Notes

05/08/2026: The ethics approval was added.
03/07/2026: Trial's existence confirmed by MHRA.